| 1 | Thalidomide Group Australia (PDF 3935 KB) Attachment 1 (PDF 15831 KB) Attachment 2 (PDF 3601 KB) |
| fa345ecc-27b2-4d77-98dc-409a45452b91~660238|7c46cb79-4ae7-4942-bcb3-692871e446ff~660238|c7120825-c415-4b19-b315-63f0a3c1fad9~660238 |
| 2 | Department of Health (PDF 280 KB) |
| dde9522c-9886-4410-8cd7-9aac937d5e02~661770 |
| 3 | Department of Social Services (PDF 1216 KB) |
| 3729faa3-04ac-41dc-9a55-cb239ed0ca6a~660212 |
| 4 | UK Thalidomide Campaigns Team (PDF 177 KB) |
| 5ea1ec6d-dce1-41e7-93c7-d99c9b592204~661821 |
| 5 | Professor Richard Madden (PDF 61 KB) |
| 9108ae9f-dd72-4a97-8a39-ce03850f0a32~661822 |
| 6 | Name Withheld (PDF 95 KB) |
| 6be65bcf-e2af-43bb-abe3-7ec13e1d0fa5~660108 |
| 7 | Confidential |
| |
| 8 | Name Withheld (PDF 43 KB) |
| 906db6fc-4d59-4cc7-b858-14f5e783755e~659743 |
| 9 | Name Withheld (PDF 32 KB) |
| 62544a78-a076-4ca6-85da-66302fef4cac~660245 |
| 10 | Name Withheld (PDF 75 KB) |
| d05e8ca9-a94b-4e91-b487-17f6093681cd~660102 |
| 11 | Name Withheld (PDF 228 KB)
11.1 Supplementary to submission 11 (PDF 76 KB) |
| a0541872-54be-4d0c-bb4f-6e404d759f8f~661847|f3f5ee03-208b-4bd3-a4f8-ce71e3bdfec6~661847 |
| 12 | Name Withheld (PDF 53 KB) |
| 768c1cad-810e-41c9-bd3d-889dc52e5566~660041 |
| 13 | Name Withheld (PDF 60 KB) |
| b063ef5e-13dc-41f2-8de2-f920cb761f53~660045 |
| 14 | Name Withheld (PDF 277 KB) |
| b1802705-5ab8-4da3-a993-921b86c864b1~660136 |
| 15 | Name Withheld (PDF 35 KB) |
| 7f944963-e21d-4bc5-af08-4f8512ccf615~659720 |
| 16 | Name Withheld (PDF 49 KB) |
| 9fe5e76a-b7e7-4d92-940a-e5f71478401e~659723 |
| 17 | Name Withheld (PDF 236 KB) |
| 80c5ac15-c554-4261-88e1-9570b9d039c6~659985 |
| 18 | Name Withheld (PDF 5306 KB) |
| 4a87956a-f605-40aa-aa21-6d3577e27232~660122 |
| 19 | Name Withheld (PDF 44 KB) |
| d2c1bef3-eae3-4660-a8d1-3c77698f69cd~660156 |
| 20 | Name Withheld (PDF 65 KB) |
| 7ef640ba-8042-4aca-b480-f19129e4f8bf~660177 |